NCT05747157 2023-11-21
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research
Anhui Provincial Hospital
Phase EARLY_PHASE1 Unknown
Clinical Trials
7 trialsNCT06056752 2023-10-24
QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Anhui Provincial Hospital
Phase 1 Recruiting
NCT05648019 2023-03-09
CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
KK Women's and Children's Hospital
Phase 2 Recruiting
NCT02618109 2022-10-03
LABMI
University Hospital, Angers
Phase 4 Terminated
NCT04411290 2020-06-02
Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Umraniye Education and Research Hospital
Unknown
NCT02924753 2017-12-29
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Henan Cancer Hospital
Phase 1 Unknown
NCT03263208 2017-10-20
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
Henan Cancer Hospital
Phase 1/2 Unknown